Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Gross Profit (2021 - 2025)

Kiniksa Pharmaceuticals International's Gross Profit history spans 5 years, with the latest figure at $181.2 million for Q4 2025.

  • For Q4 2025, Gross Profit rose 73.15% year-over-year to $181.2 million; the TTM value through Dec 2025 reached $599.9 million, up 65.57%, while the annual FY2025 figure was $599.9 million, 65.57% up from the prior year.
  • Gross Profit reached $181.2 million in Q4 2025 per KNSA's latest filing, up from $160.6 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $181.2 million in Q4 2025 to a low of -$155.0 million in Q4 2022.
  • Average Gross Profit over 5 years is $64.8 million, with a median of $69.3 million recorded in 2024.
  • The largest YoY upside for Gross Profit was 888.4% in 2022 against a maximum downside of 769.77% in 2022.
  • A 5-year view of Gross Profit shows it stood at $23.1 million in 2021, then crashed by 769.77% to -$155.0 million in 2022, then soared by 147.62% to $73.8 million in 2023, then skyrocketed by 41.77% to $104.6 million in 2024, then surged by 73.15% to $181.2 million in 2025.
  • Per Business Quant, the three most recent readings for KNSA's Gross Profit are $181.2 million (Q4 2025), $160.6 million (Q3 2025), and $138.2 million (Q2 2025).